QUINOLINE-BASED PROTEASOME INHIBITORS AND USES THEREOF
申请人:Board of Trustees of Michigan State University
公开号:US20180282280A1
公开(公告)日:2018-10-04
Described herein are quinoline compounds useful for, among other things, inhibition of the proteasome and for treatment of cancer and inflammation.
本文描述了喹啉化合物,可用于抑制蛋白酶体,治疗癌症和炎症等。
Quinoline-based proteasome inhibitors and uses thereof
申请人:Board of Trustees of Michigan State University
公开号:US10752590B2
公开(公告)日:2020-08-25
Described herein are quinoline compounds useful for, among other things, inhibition of the proteasome and for treatment of cancer and inflammation.
本文描述的喹啉化合物主要用于抑制蛋白酶体以及治疗癌症和炎症。
Substituted quinolines as noncovalent proteasome inhibitors
作者:Tanner J. McDaniel、Theresa A. Lansdell、Amila A. Dissanayake、Lauren M. Azevedo、Jacob Claes、Aaron L. Odom、Jetze J. Tepe
DOI:10.1016/j.bmc.2016.04.005
日期:2016.6
Screening of a library of diverse heterocyclic scaffolds identified substituted quinolines as inhibitors of the human proteasome. The heterocyclic library was prepared via a novel titanium-catalyzed multicomponent coupling reaction, which rendered a diverse set of isoxazoles, pyrimidines, pyrroles, pyrazoles and quinolines. SAR of the parent lead compound indicated that hydrophobic residues on the
对不同杂环支架文库的筛选鉴定出取代的喹啉作为人类蛋白酶体的抑制剂。该杂环库是通过一种新型钛催化多组分偶联反应制备的,该反应产生了多种异恶唑、嘧啶、吡咯、吡唑和喹啉。母体先导化合物的 SAR 表明苯并部分上的疏水残基显着提高了效力。先导化合物25抑制蛋白酶体的胰凝乳蛋白酶样蛋白水解活性 (IC 50 5.4 μM),代表一类新的非肽、非共价蛋白酶体抑制剂。